Automated brain morphometry for dementia diagnosis (BrainMeasure)

  • Research type

    Research Study

  • Full title

    Automated brain morphometry for dementia diagnosis (BrainMeasure)

  • IRAS ID

    132681

  • Contact name

    Sergi Costafreda Gonzalez

  • Contact email

    sergi.1.costafreda@kcl.ac.uk

  • Sponsor organisation

    King's College London

  • Research summary

    Early dementia diagnosis improves patient and carer experience, links them to appropriate care and support and
    enables timely symptomatic treatment. NICE guidelines recommend brain Magnetic resonance imaging (MRI) to
    assist with the diagnosis in suspected dementia. Recently, computerised analysis of MRI scans, also known as
    automated brain morphometry, has shown potential to detect the brain changes characteristic of early dementia, and
    may therefore be a useful addition to the standard reporting performed by a neuroradiologist. The present pilot study
    will assess whether adding brain morphometric analysis to the usual diagnostic pathway improve diagnosis in clinical
    practice as an addition to the existing diagnostic pathway in a memory clinic setting.
    Newly referred patients with suspicion of dementia will be enrolled into the study. Participants will be randomized into
    two groups: 50% will form the control group, and have their diagnosis performed in the normal way, with traditional
    radiology reports available from the MRI investigation. For the remaining half of patients, the referring clinician will
    receive, in addition to the traditional report, a brain morphometry assessment of dementia markers to assist with
    clinical decision making.
    The study will ascertain whether there are differences between the two arms in clinical diagnostic confidence (the
    confidence of the referring clinician in the diagnosis postMRI,
    as measured by a questionnaire), patient satisfaction
    with the diagnostic process, as well as time to diagnosis and several measures of patient outcomes (cognitive
    performance and neuropsychiatric symptoms) and use of clinical resources (additional facetoface
    visits and
    diagnostic testing, prescription of antidementia
    drugs and other medication) over a period of 1 year after the initial
    assessment. As well, the accuracy of the initial diagnosis will be assessed by comparing the number of patients who
    have their initial diagnosis changed over this 1 year period in both arms.

  • REC name

    London - City & East Research Ethics Committee

  • REC reference

    14/LO/0668

  • Date of REC Opinion

    16 Sep 2014

  • REC opinion

    Further Information Favourable Opinion